Overview
LifeVantage fiscal Q1 revenue increased 0.7% yr/yr but missed analyst expectations
Adjusted EPS for fiscal Q1 rose to $0.18 from $0.15 a year ago
Company highlights strategic acquisition of LoveBiome as a pivotal milestone
Outlook
Company reiterates FY 2026 revenue guidance of $225 mln to $240 mln
LifeVantage expects FY 2026 adjusted EPS of $1.00 to $1.15
Company anticipates higher H2 revenue due to seasonality and LoveBiome acquisition
Result Drivers
REGIONAL REVENUE - Revenue in the Americas increased 0.8%, while Asia/Pacific & Europe saw a 0.4% increase, with a decline when excluding currency effects
EXPENSES IMPACT - Increase in commissions and incentives expenses due to changes in sales mix and promotional programs
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q1 Revenue | Miss | $47.56 mln | $54.75 mln (2 Analysts) |
Q1 Net Income | $2.15 mln | ||
Q1 Gross Profit | $37.81 mln | ||
Q1 Operating Expenses | $35.54 mln | ||
Q1 Operating Income | $2.26 mln | ||
Q1 Pretax Profit | $2.24 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for LifeVantage Corp is $24.00, about 69.4% above its November 3 closing price of $7.34
The stock recently traded at 7 times the next 12-month earnings vs. a P/E of 12 three months ago
Press Release: ID:nGNX1qMsFW
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Comments